Related Experiment Video
Updated: Aug 12, 2026
LC-MS Analysis of Human Platelets as a Platform for Studying Mitochondrial Metabolism
Published on: April 4, 2016
[Role of molsidomine on platelet activation in coronary ischemia]
1Institut des Vaisseaux et du Sang, Hôpital Lariboisière, Paris.
Insights
Molsidomine and its metabolite SIN-1 demonstrate antiplatelet activity, inhibiting platelet aggregation and key activation pathways. This suggests potential benefits for coronary diseases by reducing thrombotic events.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Hematology
Context:
- Platelet activation markers increase during myocardial ischemia.
- Platelet suppressive agents improve prognosis in coronary artery diseases.
- Molsidomine exhibits antithrombotic properties in experimental models.
Purpose:
- To investigate the antiplatelet activities of molsidomine and its metabolite SIN-1.
- To elucidate the mechanism of action of SIN-1A on platelet activation.
- To assess the efficacy of oral molsidomine in inhibiting platelet function.
Summary:
- Molsidomine and SIN-1 show antithrombotic effects, primarily through antiplatelet actions.
- SIN-1A inhibits early platelet activation by blocking calcium influx and phospholipase activity.
- This mechanism reduces thromboxane formation and fibrinogen binding, crucial for clot formation.
- Oral molsidomine also exhibits antiplatelet properties, though with inter-individual variability.
Impact:
- Provides mechanistic insights into molsidomine's antiplatelet effects.
- Highlights potential therapeutic applications in ischemic heart disease.
- Suggests further research into optimizing molsidomine's clinical use.
Abstract:
Platelet suppressive agents have been shown to improve the prognosis of coronary diseases such as myocardial infarction and unstable angina. Several markers of platelet activation during myocardial ischemia have been found to be increased. Platelet granule constituents (beta thromboglobulin or platelet factor 4) or thromboxane B2 have been reported to be enhanced and, in some studies, to be correlated with the ischemia. Molsidomine or its active metabolite SIN-1 have antithrombotic properties in experimental models. This effect seems to be at least partly related to their antiplatelet activities. SIN-1A inhibited platelet aggregation and release reaction. Specific investigations have demonstrated that SIN-1A acts at a early stage of platelet activation inhibiting calcium influx and phospholipase activity which lead to inhibition of thromboxane formation and fibrinogen binding. Antiplatelet properties were also observed after oral administration of molsidomine but the extent of inhibition appeared to vary with the subjects.
Related Concept Videos
01:28Nitric Oxide Signaling Pathway
01:26Coronary Artery Disease II: Pathophysiology